WASHINGTON, DC – SEPTEMBER 21, 2010 – A new drug-eluting stent design demonstrated superiority over a traditional drug-eluting stent at 6 months, according to a study led by Laura Mauri, MD, Associate ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced that it has applied for CE Mark approval for its ...

Ureteral stents are widely used to relieve obstruction and protect kidney function, but they can also become blocked, ...

In the quest for increasingly thinner, smaller, and more-flexible stents, medical device designers may have compromised structural integrity in some current-generation drug-eluting stents (DES). And ...

Boston Scientific Corporation announced today the commercial launch of the AXIOS Stent and Electrocautery Enhanced Delivery System. It is designed to help physicians manage serious complications from ...

As understanding of the mechanisms of restenosis evolves, so too does drug-eluting stent (DES) technology. Given the various components, including a bare-metal stent, carrier coating, bioactive drug, ...

For patients with symptomatic coronary artery disease, the best course of action often involves implanting a drug-eluting stent into the artery where a plaque buildup is blocking blood flow to the ...

According to MarketsandMarkets™, the Gastrointestinal Stent Market is projected to grow from about USD 0.62 billion in 2026 ...

The latest and largest trial to compare durable-polymer versus biodegradable-polymer stents—this time in the setting of acute coronary syndromes—should convince the field once and for all that a ...

Medical science has come a long way from the days when coronary artery bypass graft surgery was the sole method for treating blocked coronary arteries. While the emergence of balloon angioplasty in ...

SUPERB Trial and SUPERA 500 Registry Both Demonstrate Highest Reported Patency Rates and Zero Fracture Rates Data Presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) ...